EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Entropy Neurodynamics Limited (ENP) fair value: what the stock is really worth

We calculate from audited financials what Entropy Neurodynamics Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jun 24, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · AU · ISIN AU0000433583

EN Thin data Jun 24, 2026

Entropy Neurodynamics Limited

ENP · AU

Weakest SetupStrongly overvalued and low quality.

!Fair value A$0.0170 · Strongly overvalued (−59%)
!Quality 47/100
!Expensive Growth (revenue 3y +151.6 %/yr)
!negative free cash flow
!Trails peers (2/6)
!Narrow moat 40/100
!Evidence only low, so the estimate is less certain
Watch Entropy Neurodynamics Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$2.09 A$0.0170 Fair Value A$0.0170 Aug 2020 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 24, 2026.

How to read this chart

60‑month range A$0.0170 – A$2.09 · fair‑value band A$0.0085 – A$0.0170 · the A$0.0410 price screens above the A$0.0170 fair value. Dashed = 300-day average. As of Jun 24, 2026.

Follow Entropy Neurodynamics in your weekly email

Every Wednesday you see whether Entropy Neurodynamics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States.

Show more

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. The company was formerly known as Tryptamine Therapeutics Limited and changed its name to Entropy Neurodynamics Limited in November 2025. Entropy Neurodynamics Limited was founded in 2019 and is based in Camberwell, Australia.

Stock analysis

Entropy Neurodynamics Limited (ENP) currently trades at A$0.0410, while our model-based Fair Value estimate is A$0.0170, implying the stock looks roughly 141.2% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 91/100, which puts the evidence level at low.

Scenario range: A$0.0085 (bear) to A$0.0170 (bull), the price of A$0.0410 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Entropy Neurodynamics Limited reported revenue of A$1.6M in FY2025 versus A$99.7K in FY2022, a compound +151.6%/yr. Reported net income was −A$5.3M in FY2025.

Key figures

Market cap A$56.5M (≈ $39.8M) · P/S ratio 36.1 · Net margin −300% · Return on equity −7,778% · Return on assets (EBIT) −98.7% · Operating margin −294% · Revenue (TTM) A$1.6M · Free cash flow −A$7.9M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).

What moves the price

The share trades about 7% below its 52-week high and 52% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −59%, ENP screens richer than that median.

Notify me when ENP reaches fair value

Put ENP on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 47/100

Of which business quality 46 · Market factors (momentum, volatility) 70

Profitability 2
Margins and returns on capital today
Quality Growth 78
Are margins and returns improving?
Cashflow 21
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 88
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 80
Price trend over the last 3–12 months (market factor)
52W Momentum 74
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+41.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+151.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−14,150.7% (2022) → −423.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ENP screens 141% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Entropy Neurodynamics Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Above median
Fair Value upside −58% · Below median
Profitability
Return on assets −46% · Bottom 25%
Growth and dividend
Revenue growth 0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 6.51× · Priciest 25%
P/S (TTM) 24.54× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Entropy Neurodynamics Limited · Fair Value
A$0.0170 −141%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Entropy Neurodynamics Limited Fair Value". https://www.fairvalue-calculator.com/stock/ENP

Frequently asked questions

Is Entropy Neurodynamics Limited (ENP) overvalued or undervalued?
As of Jun 24, 2026, our model estimates a fair value of A$0.0170 versus a price of A$0.0410, about −59% upside (overvalued).
What is the fair value of ENP?
Our model-based fair value for Entropy Neurodynamics Limited is A$0.0170 (as of Jun 24, 2026), built from audited fundamentals. The current price: A$0.0410.
What is the quality score of ENP?
Entropy Neurodynamics Limited has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Entropy Neurodynamics Limited (ENP)?
Our model-based price target is the fair value of A$0.0170 (as of Jun 24, 2026) from 2 valuation models. Cautious scenario A$0.0085, optimistic scenario A$0.0170. It is a calculation from audited fundamentals, not an analyst target.
What is the Entropy Neurodynamics Limited stock forecast for 2026?
Our models put fair value at A$0.0170, about −59% upside versus a price of A$0.0410 (overvalued). Cautious scenario A$0.0085, optimistic scenario A$0.0170. The calculation is refreshed regularly with new filings.
What is the revenue of Entropy Neurodynamics Limited (ENP)?
Entropy Neurodynamics Limited reported trailing-twelve-month revenue of about A$1.6M (latest available figure, as of Jun 24, 2026).
What is the intrinsic value of Entropy Neurodynamics Limited (ENP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Entropy Neurodynamics Limited it is A$0.0170 per share (as of Jun 24, 2026), against a price of A$0.0410. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Entropy Neurodynamics Limited stock overvalued or undervalued in 2026?
As of Jun 24, 2026, ENP trades above its calculated fair value: price A$0.0410, fair value A$0.0170, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ENP?
No. The price is what the market pays today (A$0.0410); the fair value is what the company's own numbers justify (A$0.0170). For Entropy Neurodynamics Limited the two are A$0.0240 per share apart. That gap is exactly why we show both numbers side by side.
How much is Entropy Neurodynamics Limited worth?
The market values Entropy Neurodynamics Limited at about A$56.5M (market capitalisation, as of Jun 24, 2026). Per share that is A$0.0410; our models calculate a fair value of A$0.0170 per share.
What do the bullish and bearish scenarios say about ENP?
Our models span a range for Entropy Neurodynamics Limited: cautious scenario A$0.0085, base A$0.0170, optimistic A$0.0170 per share (as of Jun 24, 2026, price A$0.0410). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is ENP from its 52-week high?
Entropy Neurodynamics Limited trades at A$0.0410, about 7% below its 52-week high of A$0.0440 and 52% above the low of A$0.0270 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0170 is for.
Which stocks are comparable to Entropy Neurodynamics Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Entropy Neurodynamics Limited stock attractive at the current price?
The data as of Jun 24, 2026: price A$0.0410, calculated fair value A$0.0170 (−59%), Quality Score 47/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ENP calculated?
We run Entropy Neurodynamics Limited through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0170, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Entropy Neurodynamics Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Entropy Neurodynamics Limited (ENP)?
The closing price on Sep 24, 2026 was A$0.0410. Our model-based fair value is A$0.0170, about −59% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Entropy Neurodynamics Limited right now?
The price sits above even our optimistic bull case (A$0.0170). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (A$0.0085 to A$0.0170) leaves room in how you read the outcome.

Key figures of Entropy Neurodynamics Limited

How large is the market capitalisation of Entropy Neurodynamics Limited (ENP)?
The market capitalisation of Entropy Neurodynamics Limited is A$56.5M (≈ $39.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Entropy Neurodynamics Limited (ENP)?
The price-to-sales ratio of Entropy Neurodynamics Limited is 36.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Entropy Neurodynamics Limited (ENP)?
The net margin of Entropy Neurodynamics Limited is −300% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Entropy Neurodynamics Limited (ENP)?
The return on equity (ROE) of Entropy Neurodynamics Limited is −7,778% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Entropy Neurodynamics Limited (ENP)?
On an EBIT basis the return on assets of Entropy Neurodynamics Limited is −98.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Entropy Neurodynamics Limited (ENP)?
The operating margin of Entropy Neurodynamics Limited is −294% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Entropy Neurodynamics Limited (ENP) generate?
The free cash flow of Entropy Neurodynamics Limited is −A$7.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Entropy Neurodynamics Limited (ENP) hold?
Entropy Neurodynamics Limited holds more cash than debt, A$3.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Entropy Neurodynamics Limited in the live analysis

One click puts Entropy Neurodynamics Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.